SCHEMBL3228539

SCHEMBL3228539

CCCCCCCCCCCC=CCCCCC(N)=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 4/20 1.00
SOAT1 P35610 2/20 1.00
CYP1A2 P05177 2/20 1.00
CYP2C19 P33261 2/20 1.00
KMT2A Q03164 2/20 1.00
MEN1 O00255 1/20 1.00
TP53 P04637 1/20 1.00
CYP3A4 P08684 1/20 1.00
KDM4E B2RXH2 2/20 0.89
CNR1 P21554 1/20 0.78
TERT O14746 3/20 0.70
PTPN1 P18031 3/20 0.70
PPARG P37231 3/20 0.70
PPARD Q03181 3/20 0.70
PPARA Q07869 3/20 0.70
MAPT P10636 2/20 0.70
BLM P54132 2/20 0.70
HSD17B10 Q99714 2/20 0.70
FABP4 P15090 2/20 0.70
GMNN O75496 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL284607 1.00 FAAH (1.00) FAAHSOAT1CYP1A2CYP2C19KMT2A
Oleamide SCHEMBL19814150 1.00 FAAH (1.00) FAAHSOAT1CYP1A2CYP2C19KMT2A
SCHEMBL10445439 1.00 FAAH (1.00) FAAHSOAT1CYP1A2CYP2C19KMT2A
SCHEMBL21983255 1.00 FAAH (1.00) FAAHSOAT1CYP1A2CYP2C19KMT2A
SCHEMBL23528231 1.00 FAAH (1.00) FAAHSOAT1CYP1A2CYP2C19KMT2A
SCHEMBL10445419 1.00 FAAH (1.00) FAAHSOAT1CYP1A2CYP2C19KMT2A
SCHEMBL24340776 1.00 FAAH (1.00) FAAHSOAT1CYP1A2CYP2C19KMT2A
SCHEMBL21501560 1.00 FAAH (1.00) FAAHSOAT1CYP1A2CYP2C19KMT2A
SCHEMBL21654359 1.00 FAAH (1.00) FAAHSOAT1CYP1A2CYP2C19KMT2A
SCHEMBL22419041 1.00 FAAH (1.00) FAAHSOAT1CYP1A2CYP2C19KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10450529-B2 Method for simultaneously and stably dispersing spherical nanoparticles in oil medium by using layered nanosheets and application thereof SOUTH UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA (CN) 2019-10-22 US claimed
US-20170145338-A1 METHOD FOR SIMULTANEOUSLY AND STABLY DISPERSING SPHERICAL NANOPARTICLES IN OIL MEDIUM BY USING LAYERED NANOSHEETS AND APPLICATION THEREOF SOUTH UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA (CN) 2017-05-25 US claimed
US-6440434-B1 PETROSELINIC ACID OR DERIVATIVE; AND RETINOL, RETINOIC ACID OR RETINYL LINOLEATE; TOPICAL; SKIN AGING AND WRINKLE RESISTANCE; DERMATOLOGY CONOPCO, INC. 2002-08-27 US claimed
CN-119384539-A Moisture/oil resistant composite material 世界中心加利福尼亚公司 2025-01-28 CN disclosed
US-11851396-B2 Preservative composition AKTIEGOLAGET SKF (SE) 2023-12-26 US disclosed
CN-113811580-B Preservative composition 斯凯孚公司 2023-01-24 CN disclosed
US-20220213403-A1 A PRESERVATIVE COMPOSITION AKTIEBOLAGET SKF (SE) 2022-07-07 US disclosed
CN-113811580-A Preservative composition 斯凯孚公司 2021-12-17 CN disclosed
US-20200354313-A1 SULFONATE COMPOSITION AND PRESERVATIVE COMPOSITION COMPRISING THE SULFONATE COMPOSITION SKF AB (SE) 2020-11-12 US disclosed
CN-111909753-A Sulfonate compositions and preservative compositions comprising the same 斯凯孚公司 2020-11-10 CN disclosed
US-10450529-B2 Method for simultaneously and stably dispersing spherical nanoparticles in oil medium by using layered nanosheets and application thereof SOUTH UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA (CN) 2019-10-22 US disclosed
CN-106715661-A Grease compositions 斯凯孚公司 2017-05-24 CN disclosed
WO-2016066798-A1 GREASE COMPOSITIONS AKTIEBOLAGET SKF (SE) 2016-05-06 WO disclosed
EP-1968971-B1 DIOXOLANE DERIVATES FOR THE TREATMENT OF CANCER CLAVIS PHARMA AS (NO) 2013-03-27 EP disclosed
US-8349834-B2 Dioxolane derivates for the treatment of cancer CLAVIS PHARMA AS (NO) 2013-01-08 US disclosed
US-20100062996-A1 DIOXOLANE DERIVATES FOR THE TREATMENT OF CANCER CLAVIS PHARMA AS (NO) 2010-03-11 US disclosed
EP-1968971-A1 DIOXOLANE DERIVATES FOR THE TREATMENT OF CANCER Clavis Pharma AS (NO) 2008-09-17 EP disclosed
WO-2007067071-A1 DIOXOLANE DERIVATES FOR THE TREATMENT OF CANCER CLAVIS PHARMA AS (NO) 2007-06-14 WO disclosed
US-20070135436-A1 Chemical compounds CLAVIS PHARMA AS (NO) 2007-06-14 US disclosed
EP-0355842-A2 External preparation Sansho Seiyaku Co., Ltd. (JP) 1990-02-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11851396-B2 Preservative composition CA1, CA7, CA12 FAAH 71/4885SOAT1 973/4885CYP1A2 546/4885
US-20100062996-A1 DIOXOLANE DERIVATES FOR THE TREATMENT OF CANCER FASN, ALOX5, SQLE FAAH 594/4885SOAT1 137/4885CYP1A2 568/4885
US-20070135436-A1 Chemical compounds FASN, ALOX5, ALOX15 FAAH 512/4885SOAT1 98/4885CYP1A2 976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.